Loading
MYCL (MYCL proto-oncogene, bHLH transcription factor) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer and Melanoma.
UniProt has no function text for P12524; HGNC names it "MYCL proto-oncogene, bHLH transcription factor".
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming JQ1 and I-BET151. Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.94, affected pathway 0.35, genetic association 0.00, somatic mutation 0.96).
In plain words · MYCL (MYCL proto-oncogene, bHLH transcription factor) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer and Melanoma.
MYCL (MYCL proto-oncogene, bHLH transcription factor) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer and Melanoma.
UniProt has no function text for P12524; HGNC names it "MYCL proto-oncogene, bHLH transcription factor". Location: Nucleus (UniProt).
No product in this corpus aims at MYCL yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA MYCL: RNA tissue enhanced (pancreas 64 nTPM, skin 1 37 nTPM); blood lineage group enriched (dendritic cells 23 nTPM, monocytes 17 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas MYCL tissue; Open Targets ENSG00000116990 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: DePinho R.A. et al, Genes Dev, 1987, "The human myc gene family: structure and activity of L-myc and an L-myc pseudogene". Source.
Sources: HGNC HGNC:7555 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P12524 (protein name, function text, keywords and locations (REST API)); CIViC gene MYCL (1 evidence items, 0 assertions, 1 variants; diseases: Multiple Myeloma (GraphQL API, CC0)); Open Targets ENSG00000116990 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: melanoma 0.55, skin cancer 0.56 (GraphQL API, CC0))
UniProt has no function text for P12524; HGNC names it "MYCL proto-oncogene, bHLH transcription factor". Location: Nucleus (UniProt). Locus 1p34.2 (HGNC).
RNA: tissue enhanced (pancreas 64 nTPM, skin 1 37 nTPM), detected in many normal tissues. Blood: group enriched (dendritic cells 23 nTPM, monocytes 17 nTPM).
No normal tissue stained high.
RNA cancer enhanced: Bladder Urothelial Carcinoma 63 pTPM.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
The organising framework for every small-cell lung cancer trial designed since. It is also why the slow progress in the disease is now attributed to treating four diseases as one rather than to the biology being intractable.
Why small-cell lung cancer has no targeted therapy in the conventional sense: it is built from the loss of TP53 and RB1, and the drugs that transformed non-small-cell disease inhibit gains rather than restore losses. The NOTCH result pointed at DLL3 and, eventually, at tarlatamab.
Query for this target: (TITLE:"MYCL" OR ABSTRACT:"MYCL" OR TITLE:"MYCL proto-oncogene, bHLH transcription factor" OR ABSTRACT:"MYCL proto-oncogene, bHLH transcription factor" OR TITLE:"bHLHe38" OR ABSTRACT:"bHLHe38" OR TITLE:"MYCL1" OR ABSTRACT:"MYCL1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MYCL, not a curated reading list.
Shares Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, Comprehensive genomic profiles of small cell lung cancer.
Shares Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, CIViC, Open Targets Platform.
Shares Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, CIViC.
Shares Comprehensive genomic profiles of small cell lung cancer, CIViC, Open Targets Platform.
Shares Comprehensive genomic profiles of small cell lung cancer, CIViC, Open Targets Platform.
Shares Comprehensive genomic profiles of small cell lung cancer, CIViC, Open Targets Platform.
Shares Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, Comprehensive genomic profiles of small cell lung cancer.
Shares Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, Comprehensive genomic profiles of small cell lung cancer, Skin cancer (all types), CIViC.